Want to see TELA full AI Analyst Report?
TELA Stock Chart & Stats
$0.74
$0.04(1.41%)
At close: 4:00 PM EST
$0.74
$0.04(1.41%)
Day’s Range― - ―
52-Week Range$0.50 - $2.19
Previous CloseN/A
Volume34.27K
Average Volume (3M)90.44K
Market Cap
$32.72M
Enterprise Value$52.35
Total Cash (Recent Filing)$39.54M
Total Debt (Recent Filing)$56.39M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 10, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding44,766,148
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.67Price Target Upside125.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$86.71M
Bulls Say, Bears Say
Bulls Say
Product Portfolio / DifferentiationThe OviTex LTR fully resorbable portfolio represents a structural product differentiation within hernia repair. A unique resorbable offering can expand addressable procedures, align with surgeon preferences, and sustain pricing competitiveness long-term, supporting durable adoption and clinical momentum.
International Expansion / NHS AdoptionRapid international growth and NHS procurement provide durable commercial validation and diversified revenue streams. Success in EU health systems signals transferable cost/clinical value, reducing single-market dependency and improving long-term scaling prospects across national health systems.
Unit Growth And Product EconomicsSustained unit volume growth combined with high gross margins indicates robust product economics. Healthy margins create leverage as commercial scale improves, enabling potential path to profitability if fixed operating costs are absorbed by higher volumes over the next several quarters.
Bears Say
Weak Capitalization / Negative EquityNegative shareholders' equity and meaningful debt materially weaken financial flexibility. Persistent negative equity elevates refinancing and covenant risk, making the business more dependent on external capital to fund growth or absorb losses, a durable constraint on strategic options.
Ongoing Cash BurnMaterial negative operating and free cash flow imply reliance on financing or substantial commercial improvement to sustain operations. Even with improvement, continued cash burn makes runway contingent on execution or capital markets access, a persistent risk to long-term independence.
Execution & Concentration RiskAchieving projected growth relies on newly hired reps maturing and timely contract wins. Concentration of PRS utilization among few high-ASP implanters and timing sensitivity create structural execution risk: slower rep productivity or lost key users can meaningfully delay scale and profitability.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.50 and its highest was $2.19 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $32.72M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Aug 10, 2026 which is in 20 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on May 12, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.184 by -$0.026.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.17.
How many shares outstanding does TELA Bio have?
TELA Bio has 44,766,148 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.184. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TELA Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.67 (125.23% Upside)
$1.67 (125.23% Upside)
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.53%
Trailing 12-Months
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Stock 12 Month Forecast
Average Price Target
$1.67
▲(125.23% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
20.80% Insiders
4.91% Mutual Funds
50.68% Other Institutional Investors
20.16% Public Companies and
Individual Investors